Strategies Employed for the Development of PARP Inhibitors-Reference-Cited by-同舟云学术

Strategies Employed for the Development of PARP Inhibitors

Published:2017 Issue: Volume: Page:271-297
ISSN:1064-3745
Container-title:Methods in Molecular Biology
language:
Short-container-title:

Author:

Canan Stacie,Maegley Karen,Curtin Nicola J.

Publisher

Springer New York

Link

http://link.springer.com/content/pdf/10.1007/978-1-4939-6993-7_18

Reference20 articles.

1. Bai P (2015) Biology of poly(ADP-ribose) polymerases: the factotums of cell maintenance. Mol Cell 58:947–958

2. Durkacz BW, Omidiji O, Gray DA et al (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283:593–596

3. Ben-Hur E, Chen CC, Elkind MM (1985) Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations and enhancement of radiation response in Chinese hamster cells. Cancer Res 45:2123–2127

4. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. Nature 434:913–917

5. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling;Cancers;2022-11-12

2. Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling;2022-01-24

3. Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells;Cancers;2020-04-04